Literature DB >> 23263827

Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome.

Yizhuo Zhang1, Qing Guo, Haifeng Zhao, Dandan Zhao, Xiaoxiong Wu, Weipeng Zhao, Yafei Wang, Bing Xia, Wanming Da.   

Abstract

CXCR4 is the receptor of stromal cell-derived factor (SDF-1) and is expressed in many types of cancer cells. It also plays an important role in metastasis of malignant disease. In this study, we detected the expression of CXCR4 in 81 patients with myelodysplastic syndrome (MDS) by flow cytometry. We categorized MDS patients into the high-expression group and low-expression group according to CXCR4 mean florescence intensity ration thresholds. We showed that the high-expression group had a shorter overall survival time and shorter relapse-free survival time compared with those of the low-expression group (21.6 ± 1.9 vs. 46.0 ± 1.6 months, 17.0 ± 1.9 vs. 42.5 ± 2.1 months, respectively, P < 0.05), and Cox regression showed that CXCR4 was an independent prognostic factor. We conclude that the expression of CXCR4 is a useful prognostic factor for patients with MDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263827     DOI: 10.1007/s12032-012-0341-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma.

Authors:  Bao-Cheng Zhao; Zhen-Jun Wang; Wei-Zheng Mao; Hua-Chong Ma; Jia-Gang Han; Bo Zhao; Hui-Min Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  CXCR4 is a prognostic marker in acute myelogenous leukemia.

Authors:  Anke C Spoo; Michael Lübbert; William G Wierda; Jan A Burger
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

3.  SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis.

Authors:  Yizhuo Zhang; Haifeng Zhao; Dandan Zhao; Lu Sun; Yaqin Zhi; Xiaoxiong Wu; Wenrong Huang; Wanming Da
Journal:  Leuk Res       Date:  2011-07-28       Impact factor: 3.156

4.  Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

Authors:  U Germing; B Hildebrandt; M Pfeilstöcker; T Nösslinger; P Valent; C Fonatsch; M Lübbert; D Haase; C Steidl; O Krieger; R Stauder; A A N Giagounidis; C Strupp; A Kündgen; T Mueller; R Haas; N Gattermann; C Aul
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

5.  The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes.

Authors:  Chang Chunkang; Yang Rui; Xu Feng; Guo Juan; Zhang Xi; Wu Lingyun; Li Xiao; Wang Jianmin
Journal:  Med Oncol       Date:  2010-09-22       Impact factor: 3.064

6.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Saskia M C Langemeijer; Roland P Kuiper; Ruth Knops; Marion Massop; Evelyn R L T M Tönnissen; Adrian van der Heijden; Theresia N Scheele; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

Review 7.  Myelodysplastic syndromes: an update on molecular pathology.

Authors:  Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

Review 8.  The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.

Authors:  Jianhua Wang; Robert Loberg; Russell S Taichman
Journal:  Cancer Metastasis Rev       Date:  2006-12       Impact factor: 9.264

Review 9.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

Review 10.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

View more
  4 in total

1.  A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.

Authors:  Eric Huselton; Michael P Rettig; Theresa Fletcher; Julie Ritchey; Leah Gehrs; Kyle McFarland; Stephanie Christ; William C Eades; Kathryn Trinkaus; Rizwan Romee; Shashikant Kulkarni; Armin Ghobadi; Camille Abboud; Amanda F Cashen; Keith Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; John F DiPersio; Mark A Schroeder
Journal:  Leuk Lymphoma       Date:  2021-01-19

Review 2.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

Review 3.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10

4.  Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.

Authors:  Tingyong Cao; Yuanxin Ye; Hongyan Liao; Xiao Shuai; Yongmei Jin; Jun Su; Qin Zheng
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.